Clinical Trials | June 26, 2024
Imfinzi improved event-free survival and overall survival for bladder cancer
First immunotherapy regimen before and after surgery to extend survival in bladder cancer
First immunotherapy regimen before and after surgery to extend survival in bladder cancer
Innovative technology represents a breakthrough scientific achievement for highly contagious respiratory disease
GL0034 administered once-weekly confirmed clinically meaningful weight loss and improved glucometabolic parameters over a 4-week treatment period in individuals with obesity
Renews GMP certifications for India and Malaysia sites
The company will now explore a buyer for its manufacturing site and exit in due course
Approval based on CAPItello-291 results which showed this combination reduced the risk of disease progression or death by 50% vs. Faslodex alone in a biomarker-altered population
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Leukemia
Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas
Subscribe To Our Newsletter & Stay Updated
